

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/644,588-Conf. #5265
				Filing Date	August 20, 2003
				First Named Inventor	Connie Sanchez
				Art Unit	1614
				Examiner Name	T. E. Betton
(Use as many sheets as necessary)				Attorney Docket Number	05432/100M919-US3
Sheet	1	of	6		

## U.S. PATENT DOCUMENTS

#### FOREIGN PATENT DOCUMENTS

Examiner Signature \_\_\_\_\_ Date Considered \_\_\_\_\_

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant." CITE NO. Those application(s) which are marked with a single asterisk (\*) next to the citation No are not supplied (under 37 CFR 1.98(b)(2)(ii)(B)) because that application was filed after June 30, 2003 or is available in the IFW. "Applicant's citation designation number (optional)." The USPTO's Citation Document at [www.uspto.gov](http://www.uspto.gov) or MPEP 9104.3 "Enter Office that issued the citation." The Office that issued the citation document, as indicated by the year of the reign of the Emperor. "Priority date (optional)." The date the application was filed. "Priority number (optional)." The priority number of the parent application. "Priority document by the appropriate symbol(s), as indicated on the document under WIPO Standard ST 16 if applicable." Applicant is to place a check mark here if EPOien (Invention Translation) is attached.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				Application Number	10/644,588-Conf. #5265
				Filing Date	August 20, 2003
				First Named Inventor	Connie Sanchez
				Art Unit	1614
				Examiner Name	T. E. Bettton
Sheet	2	of	6	Attorney Docket Number	05432/100M919-US3

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	7	Notice of Opposition to European Patent No. 1 200 081 filed by EGIS GYOGYSZERGYAR NYRT. (June 14, 2007).			
	8	Notice of Opposition to European Patent No. 1 200 081 filed by GENERICS (UK) LIMITED. (June 19, 2007).			
	9	Notice of Opposition to European Patent No. 1 200 081 filed by HEXAL PHARMA AG. (June 20, 2007).			
	10	Notice of Opposition to European Patent No. 1 200 081 filed by Pliva Hrvatska d.o.o. (June 21, 2007).			
	11	Notice of Opposition to European Patent No. 1 200 081 filed by RICHTER GEDEON R.T. (June 20, 2007).			
	12	Notice of Opposition to European Patent No. 1 200 081 filed by TEVA PHARMACEUTICAL INDUSTRIES LTD. (June 20, 2007).			
	13	NZ Examination Report			
	14	ARIENS, E. J. "Chirality in Biopactive Agents and its Pitfalls." TIPS, May 1986:200-205.			
	15	P. BAUMANN, "Care of depression in the elderly: comparative pharmacokinetics of SSRIs," International Clinical Psychopharmacology 1998, Vol. 13 (suppl 5) S35-S43.			
	16	BOERNER, R.J. et al. "The Importance of new Antidepressants in the Treatment of Anxiety/Depressive Disorders. Pharmacopsychiat. 32 (1999): 119-126.			
	17	G. BONDOLFI, "Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation." Psychopharmacology (1996) 128:421-425.			
	18	O. BRAWMAN-MINTZER, "Psychiatric Comorbidity in Patients with Generalized Anxiety Disorder," Am J Psychiatry 150:8, August 1993, pp 1216 - 1218.			
	19	K. M. CONNOR, "Generalized Anxiety Disorder: Neurobiological and Pharmacotherapeutic Perspectives." Biol Psychiatry 1998; 44:1286-1294.			
	20	Neal R. CUTLER, "A Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ipsapirone Versus Lorazepam in Patients With Generalized Anxiety Disorder: A Prospective Multicenter Trial," Journal of Clinical Psychopharmacology, Vo. 13, No. 6, (1993), pp. 429-437.			
	21	Larry CULPEPPER, M.D., "Escitalopram: A New SSRI for the Treatment of Depression in Primary Care," Primary Care Companion J. Clin Psychiatry 2002;4(6) pp 209 - 214.			

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				Application Number	10/644,588-Conf. #5265
				Filing Date	August 20, 2003
				First Named Inventor	Connie Sanchez
				Art Unit	1614
				Examiner Name	T. E. Betton
Sheet	3	of	6	Attorney Docket Number	05432/100M919-US3

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	22	N. P. EMMANUEL, "Sertraline in Generalized Anxiety Disorder, A Case Series," <i>Psychopharmacology Bulletin</i> p. 518			T <sup>2</sup>
	23	Fachinformation, Cipralex (10 mg/20 mg)			
	24	Fachinformation, Cipramil (20 mg/40 mg)			
	25	FDA's Policy Statement for the Development of New Stereoisomeric Drugs, FDA website, < <a href="http://www.fda.gov/cder/guidance/stereo.htm">http://www.fda.gov/cder/guidance/stereo.htm</a> >, printed September 5, 2007			
	26	"Forest Aerobics Market Share is Stable at 10%-10.5%, Firm Reports. (September 28, 1998) Vol. 60, No. 39, pg. 19.			
	27	Shinji HASHIMOTO, Effects of conditioned fear stress on serotonin neurotransmission and freezing behavior in rats, <i>European Journal of Pharmacology</i> 378 (1999) 23-30.			
	28	Shinji HASHIMOTO, Effects of the Co-administration of 5-HT1a Receptor Antagonists with an SSRI in Conditioned Fear Stress-Induced Freezing Behavior, <i>Pharmacology Biochemistry and Behavior</i> , Vol. 58, No. 2, pp. 471-475, 1997.			
	29	Shinji HASHIMOTO, Serotonin reuptake inhibitors reduce conditioned fear stress-induced freezing behavior in rats, <i>Psychopharmacology</i> (1996) 123: pp. 182-186.			
	30	S. HOGG, The antidepressant effects of citalopram are mediated by the S-(+) and not the R(-) enantiomer, <i>European Neuropsychopharmacology</i> , Vol. 9, Supplement 5, 1999, p. S213.			
	31	A.J. HUTT, "Drug Chirality and its Clinical Significance," <i>Drugs</i> 1996: 52, Suppl. 5, pp. 1-12.			
	32	Takeshi INOUE, Serotonergic Activation Reduces Defensive Freezing in the Conditioned Fear Paradigm, <i>Pharmacology Biochemistry and Behavior</i> , Vol. 53, No. 4, pp. 825-831, 1996.			
	33	M. KOSEL, Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography, <i>Journal of Chromatography B</i> , 719 (1998) pp. 234-238.			
	34	Y.W. Francis LAM, Pharm. D. Stereoselectivity: An Issue of Significant Importance in Clinical Pharmacology, <i>Pharmacotherapy</i> , Vol. 8, No. 3, 1988, pp 147-157.			
	35	G. LAUX, Psychopharmacological Treatment of Anxiety Disorders, <i>Therapeutische Umschau</i> , Vol. 54, No. 10, 1997, p. 595-599.			
	36	LEPOLA et al., Citalopram in Anxiety Disorder of Childhood and Adolescence, <i>Eur. Child. Adol. Psych.</i> , 1994 3(4):277-279.			
	37	LEPOLA et al., The effect of citalopram in panic disorder and agoraphobia, <i>Nord. J. Psych.</i> , 1994, 48:13-17.			
	38	J.P. LHUILLIER, Maprotiline Drops: Pilot Study in Anxiety Adaptive Disorders, <i>Psychiatry Today: Accomplishments and Promises</i> , International Congress Series, Elsevier Science Publishers B.V., 1989.			
	39	Lundbeck Annual Report 1999			
	40	Lundbeck Annual Report 1998			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/644,588-Conf. #5265
				Filing Date	August 20, 2003
				First Named Inventor	Connie Sanchez
				Art Unit	1614
				Examiner Name	T. E. Betton
Sheet	4	of	6	Attorney Docket Number	05432/100M919-US3

NON PATENT LITERATURE DOCUMENTS					
Examiner initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	41	R. B. LYDIARD, Recent Developments in the Psychopharmacology of Anxiety Disorders, Journal of Consulting and Clinical Psychology 1996 Vol. 64, No. 4, pp 660-668.			
	42	W. MAIER, The Epidemiology of comorbidity between depression, anxiety disorders and somatic diseases, International Clinical Psychopharmacological, May 1999: 14 Suppl 2: S1-6.			
	43	MONTGOMERY SA & Asberg M, "A new depression scale designed to be sensitive to change", 1979, Br. J. of Psychiatry; 134:382-389			
	44	S. NOBLE, Citalopram: A Review of its Pharmacology, Clinical Efficacy, and Tolerability in the Treatment of Depression, CNS Drugs 1997 Nov; 8 (5): 410-431			
	45	G. PARKER, Early onset depression: the relevance of anxiety, Soc Psychiatry Psychiatr Epidemiol (1997) 32: 30-37.			
	46	Psychopharmaka Rote Liste 1998, p. 127.			
	47	RAGNESKOG et al., Long-Term Treatment of Elderly Individuals With Emotional Disturbances: An Open Study With Citalopram, Int. Psychoger., 1996 8(4):659-668.			
	48	Karl RICHELÉS, M.D., Antidepressants for the Treatment of Generalized Anxiety Disorder, Arch Gen Psychiatry Vol. 50, Nov. 1993, pp 884-895.			
	49	P. ROCCA, Paroxetine efficacy in the treatment of generalized anxiety disorder, Acta Psychiatr Scand 1997: 95: 444-450.			
	50	B. ROCHAT, Analysis of Enantiomers of Citalopram and Its Demethylated Metabolites in Plasma of Depressive Patients Using Chiral Reverse-Phase Liquid Chromatography, Therapeutic Drug Monitoring, 17:273-279 (1995).			
	51	SANCHEZ et al., R-Citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety, Pharm. Biol., 2003 75:903-907.			
	52	Jagdev SIDHU, Steady-State Pharmacokinetics of the Enantiomers of Citalopram and Its Metabolites in Humans, Chirality 9:688-692 (1997).			
	53	T. SILVERSTONE, Drugs in the treatment of Anxiety, New Zealand Journal of Psychology Vol. 25, No. 1, June 1996.			
	54	L. A. SORBERA, Escitalopram Oxalate, Drugs of the Future 2001 26(2): 115-120.			
	55	E.H. UHLENHUTH, International Study of Expert Judgment on Therapeutic Use of Benzodiazepines and Other Psychotherapeutic Medications: VI. Trends in Recommendations for the Pharmacotherapy of Anxiety disorders, 1992-1997, Depression and Anxiety 9:107-119 (1999).			
	56	WADE et al., The effect of citalopram in panic disorder, Br. J. Psychiatry, 1997, 170:549-553			
	57	BROWN et al., Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 56(1):30-34 Jan 1995 (abstract)			

Examiner Signature	Date	
	Considered	

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				Application Number	10/644,588-Conf. #5265
				Filing Date	August 20, 2003
				First Named Inventor	Connie Sanchez
				Art Unit	1614
				Examiner Name	T. E. Bettton
Sheet	5	of	6	Attorney Docket Number	05432/100M919-US3

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	58	BURKE, William J., et al. Switching Depressed Patients from Citalopram to Escitalopram is Well Tolerated and Effective. 42nd Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico. December 7-11, 2003			
	59	JOFFE et al., Response to an open trial of a second SSRI in major depression J Clin Psychiatry 57(3):114-5 Mar 1996 (abstract)			
	60	THASE, M.E., et al. Citalopram treatment of fluoxetine nonresponders. J. Clin. Psychiatry. 62(9):683-7. Sept. 2001			
	61	ZIMBROFF, Dan L., et al. Escitalopram Treatment of SSRI Non-Responders Can Lead to Remission in Patients Who Fail Initial SSRI Therapy. 24th Collegium Internationale Neuropsychopharmacologicum Congress. Paris, France. June 20-24, 2004			
	62	ZIMBROFF, Dan L., et al. Escitalopram Treatment of SSRI Non-Responders Can Lead to Remission in Patients Who Fail Initial SSRI Therapy. Posters S348, P02.164. June 23-24, 2004 (abstract)			
	63	GORMAN JM et al., "Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials." 2002 April CNS Spectr. 7(4 Suppl 1): 40-44			
	64	PATRIS M, et al., "Citalopram versus fluoxetine, a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice," 1996 International Clin Psychopharmacol 11: 129-136			
	65	Final Office Action for U.S. Patent Appl. No. 10/644,587 (Oct 17, 2007)			
	66	Non-Final Office Action for U.S. Patent Appl. No. 10/468,685 (Mar 13, 2006)			
	67	Response to Non-Final Office Action for U.S. Patent Appl. No. 10/468,685 (Sep 13, 2006)			
	68	Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (1994)			
	69	Declaration of Jeffrey M. Jonas, M.D. (Sep 13, 2006) ("Sep 13, 2006 Jonas Declaration")			
	70	Sep 13, 2006 Jonas Declaration Exhibit A: Jeffrey M. Jonas, M.D. curriculum vitae			

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/644,588-Conf. #5265
(Use as many sheets as necessary)				Filing Date	August 20, 2003
Sheet	6	of	6	First Named Inventor	Connie Sanchez
				Art Unit	1614
				Examiner Name	T. E. Betton
				Attorney Docket Number	05432/100M919-US3

<b>NON PATENT LITERATURE DOCUMENTS</b>		
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
71	Sep 13, 2006	Jonas Declaration Exhibit B: Efficacy Data from MDD Studies
72	Sep 13, 2006	Jonas Declaration Exhibit C: Burke et al., J. Clin Psychiatry, 63:4 (Apr 2002)
73	Sep 13, 2006	Jonas Declaration Exhibit D: Lexapro® Label (2002)
74		Final Office Action for U.S. Patent Appl. No. 10/468,685 (Feb 21, 2007)
75		Response to Final Office Action for U.S. Patent Appl. No. 10/468,685 (Aug 17, 2007)
76		Office Action for U.S. Patent Appl. No. 10/637,822 (Apr 16, 2004)
77		Response to Office Action for U.S. Patent Appl. No. 10/637,822 (Oct 18, 2004)
78		Celexa® Label (2004)
79		Final Office Action for U.S. Patent Appl. No. 10/637,822 (Jan 21, 2005)
80		Response to Final Office Action for U.S. Patent Appl. No. 10/637,822 (Jul 21, 2005)
81		Office Action for U.S. Patent Appl. No. 10/637,822 (Sep 30, 2005)
82		Response to Office Action for U.S. Patent Appl. No. 10/637,822 (Mar 30, 2006)
83		Final Office Action for U.S. Patent Appl. No. 10/637,822 (Aug 16, 2006)
84		Office Action for U.S. Patent Appl. No. 10/637,822 (Sep 21, 2007)
85		Response to Office Action filed October 18, 2004 for U.S. Patent Application No. 10/637,822
86		Response to Office Action filed July 21, 2005 for U.S. Patent Application No. 10/637,822
87		Celexa labeling (citalopram hydrobromide) (2004)
88		International Search Report for International Application No. PCT/DK02/00281

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.